Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms 2Breast Neoplasms 2Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Multiple Myeloma 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Burkitt Lymphoma 1Breast Carcinoma In Situ 1Brain Neoplasms 1Blood Protein Disorders 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Dexamethasone 7Lenalidomide 5isatuximab 3fludarabine 3daratumumab 3Cyclophosphamide 3Bortezomib 3pomalidomide 2Tacrolimus 2Alemtuzumab 2plerixafor 1ofatumumab 1nirogacestat 1fludarabine phosphate 1Whole-Body Irradiation 1Tissue Banks 1Thalidomide 1Stem Cell Transplantation 1Rifaximin 1Ranitidine 1Mycophenolic Acid 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Doxorubicin 1Diphenhydramine 1Clonal Hematopoiesis 1Cisplatin 1Chromatin Immunoprecipitation Sequencing 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Paraproteinemias × Ranitidine × Clear all
NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡